Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer
Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.
Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.
A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.
The IMblaze370 trial did not meet the primary endpoint.
Ramucirumab prolonged progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory hepatocellular carcinoma (HCC).
Results from the KEYNOTE-061 were presented at ESMO World GI 2018.
Prior to this study, there were no conclusive data directly comparing these regimens.
A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.
Researchers sought to determine if autophagy-related proteins are associated with survival among patients with CRC.
CORRECT and CONCUR trials demonstrated an improvement in OS for patients receiving regorafenib compared with placebo.
Researchers identified potential targets for a companion diagnostic tests using poly-ligand profiling (PLP) to determine which patients with locally advanced or metastatic pancreatic cancer may benefit from gemcitabine plus evofosfamide.